Alkermes plc

Healthcare

NASDAQ:ALKS · NASDAQ Global Select

Market Cap $7.38B Beta 0.33 P/E (TTM) 48.2

$44.28 -1.42%

-$0.64 today

52W Low $25.17High $45.76

Vol 1.46M · Avg 2.34M

EPS (TTM)$0.92

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+48.44%

Period High

$44.92

Period Low

$26.13

Latest

$44.28

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

$10.50B

TG Therapeutics, Inc.

NASDAQ:TGTX

$7.58B

Kymera Therapeutics, Inc.

NASDAQ:KYMR

$7.09B

Protagonist Therapeutics, Inc.

NASDAQ:PTGX

$7.06B

Vaxcyte, Inc.

NASDAQ:PCVX

$6.85B

Arcellx, Inc.

ACLX

$6.73B

PTC Therapeutics, Inc.

NASDAQ:PTCT

$6.23B

CRISPR Therapeutics AG

NASDAQ:CRSP

$4.80B

Akero Therapeutics, Inc.

AKRO

$4.50B

ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

$3.61B

What is the latest ALKS filing?

The latest filing shown is 4 dated Jun 12, 2026.

How many recent filings does ALKS have?

Intrinsic Alpha currently shows 20 recent filings for ALKS.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.